Daniel Klintman
Overview
Explore the profile of Daniel Klintman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergqvist V, Holmgren J, Klintman D, Marsal J
Aliment Pharmacol Ther
. 2022 Aug;
56(5):922-923.
PMID: 35934847
No abstract available.
2.
Bergqvist V, Holmgren J, Klintman D, Marsal J
Aliment Pharmacol Ther
. 2022 Jun;
56(2):351-352.
PMID: 35748834
No abstract available.
3.
Bergqvist V, Holmgren J, Klintman D, Marsal J
Aliment Pharmacol Ther
. 2022 Apr;
55(11):1389-1401.
PMID: 35470449
Background And Aims: Vedolizumab is a gut-selective treatment approved for Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of vedolizumab was approved. The aims of this study...
4.
Hagstrom H, Ndegwa N, Jalmeus M, Ekstedt M, Posserud I, Rorsman F, et al.
Liver Int
. 2021 Jan;
41(3):545-553.
PMID: 33450138
Background & Aims: Mutations in the HFE gene can lead to hereditary haemochromatosis (HH) and have been suggested to increase the risk of extra-hepatic diseases, especially breast and colorectal cancer....
5.
Efe C, Al Taii H, Ytting H, Aehling N, Bhanji R, Hagstrom H, et al.
Dig Dis Sci
. 2018 Mar;
63(5):1348-1354.
PMID: 29569003
Background: We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard...
6.
Efe C, Hagstrom H, Ytting H, Bhanji R, Muller N, Wang Q, et al.
Clin Gastroenterol Hepatol
. 2017 Jun;
15(12):1950-1956.e1.
PMID: 28603052
Background & Aims: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control...
7.
Sargenti K, Johansson A, Bertilsson S, Mattsby-Baltzer I, Klintman D, Kalaitzakis E
Dig Dis Sci
. 2016 Mar;
61(8):2294-2302.
PMID: 27010544
Background: Cirrhosis represents a state of functional immune paresis with increased infection risk. Aims: To investigate polymorphonuclear (PMN) leukocyte and monocyte function in ambulatory cirrhotics, and their potential relation with...
8.
Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, et al.
Scand J Gastroenterol
. 2013 Jul;
48(9):1027-32.
PMID: 23889159
Objective: Iron deficiency and anemia are being increasingly recognized as a complication of inflammatory bowel disease (IBD). The aim of this study was to observe, in a non-interventional way, how...
9.
Klintman D, Li X, Santen S, Schramm R, Jeppsson B, Thorlacius H
Ann Surg
. 2005 Dec;
242(6):830-8, discussion 838-9.
PMID: 16327493
Objective: To determine the role of p38 mitogen-activated protein kinase (MAPK) signaling in endotoxin-induced liver injury. Background: MAPKs have been reported to play a potential role in regulating inflammatory responses,...
10.
Klintman D, Li X, Sato T, Wang Y, Jeppsson B, Thorlacius H
Ann Surg
. 2004 Dec;
240(6):1065-72.
PMID: 15570211
Objective: To determine the role of tumor necrosis factor alpha (TNF-alpha) and Fas ligand (FasL, CD95L) in superantigen-induced and endotoxin-induced liver injury. Summary Background Data: Gram-positive bacteria are increasingly common...